Kim Schadt

814 total citations
10 papers, 541 citations indexed

About

Kim Schadt is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, Kim Schadt has authored 10 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Cellular and Molecular Neuroscience and 6 papers in Neurology. Recurrent topics in Kim Schadt's work include Mitochondrial Function and Pathology (8 papers), Genetic Neurodegenerative Diseases (8 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Kim Schadt is often cited by papers focused on Mitochondrial Function and Pathology (8 papers), Genetic Neurodegenerative Diseases (8 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Kim Schadt collaborates with scholars based in United States, Australia and Israel. Kim Schadt's co-authors include David R. Lynch, Virginia A. Stallings, Babette S. Zemel, Phoebe Thorpe, David S. Freedman, Mary Pipan, James W. Mier, Michael B. Atkins, David Avigan and Virginia F. Borges and has published in prestigious journals such as PEDIATRICS, Clinical Cancer Research and Journal of the Neurological Sciences.

In The Last Decade

Kim Schadt

10 papers receiving 530 citations

Peers

Kim Schadt

MB

IMMUN

CMN

ONCOL

NEURO

Alice W. Lee United States

Sung-Nam Cho United States

Konstantinos Douroudis United Kingdom

M. Lange Germany

S Vlaho Germany

F. Hanefeld Germany

Graziella Callari Italy

Isabelle Korn‐Lubetzki Israel

Bobbak Mansouri United States

Rabab Debs France

Alice W. Lee United States

Kim Schadt

213 ×0.8

MB

80 ×0.4

IMMUN

156 ×0.9

CMN

69 ×0.5

ONCOL

14 ×0.2

NEURO

Citations per year, relative to Kim Schadt Kim Schadt (= 1×) peers Alice W. Lee

Countries citing papers authored by Kim Schadt

Since Specialization

Citations

This map shows the geographic impact of Kim Schadt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Schadt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Schadt more than expected).

Fields of papers citing papers by Kim Schadt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Schadt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Schadt. The network helps show where Kim Schadt may publish in the future.

Co-authorship network of co-authors of Kim Schadt

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Schadt. A scholar is included among the top collaborators of Kim Schadt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Schadt. Kim Schadt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Lynch, David R., Susan Perlman, & Kim Schadt. (2024). Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations. Expert Review of Neurotherapeutics. 24(3). 251–258. 12 indexed citations

2.

Schadt, Kim, et al.. (2022). Friedreich Ataxia: Clinical Features and New Developments. Neurodegenerative Disease Management. 12(5). 267–283. 39 indexed citations

3.

Lynch, David R., Kim Schadt, Elizabeth Kichula, Shana E. McCormack, & Kimberly Y. Lin. (2021). Friedreich Ataxia: Multidisciplinary Clinical Care. Journal of Multidisciplinary Healthcare. Volume 14. 1645–1658. 27 indexed citations

4.

Lynch, David R., Lauren Hauser, Yi Dong, et al.. (2019). Randomized, double‐blind, placebo‐controlled study of interferon‐γ 1b in Friedreich Ataxia. Annals of Clinical and Translational Neurology. 6(3). 546–553. 30 indexed citations

5.

Schadt, Kim, et al.. (2019). New developments in pharmacotherapy for Friedreich ataxia. Expert Opinion on Pharmacotherapy. 20(15). 1855–1867. 28 indexed citations

6.

Shinnick, Julianna, Kim Schadt, Linda J. Addonizio, et al.. (2017). Cardiac transplantation in Friedreich Ataxia: Extended follow-up. Journal of the Neurological Sciences. 375. 471–473. 11 indexed citations

7.

Zemel, Babette S., Mary Pipan, Virginia A. Stallings, et al.. (2015). Growth Charts for Children With Down Syndrome in the United States. PEDIATRICS. 136(5). e1204–e1211. 132 indexed citations

8.

Sutton, Martin St. John, Bonnie Ky, Sean R. Regner, et al.. (2013). Longitudinal Strain in Friedreich Ataxia: A Potential Marker for Early Left Ventricular Dysfunction. Echocardiography. 31(1). 50–57. 23 indexed citations

9.

Regner, Sean R., Nicholas S. Wilcox, Lisa S. Friedman, et al.. (2012). Friedreich Ataxia Clinical Outcome Measures. Journal of Child Neurology. 27(9). 1152–1158. 36 indexed citations

10.

Avigan, David, Baldev Vasir, Jianlin Gong, et al.. (2004). Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses. Clinical Cancer Research. 10(14). 4699–4708. 203 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact